Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2865-2877

  Goshima, Fumi ^a   Esaki, Shinichi ^a,b   Luo, Chenhong ^a   Kamakura, Maki ^a   Kimura, Hiroshi ^a   Nishiyama, Yukihiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

amplicon; GM CSF; HSV; immunotherapy; ovarian cancer

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HERPES SIMPLEX VIRUS 1; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PERITONEUM TUMOR; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME; TUMOR IMMUNITY; VIRAL GENE THERAPY; VIRUS GENE; VIRUS STRAIN; VP5 GENE;

AMPLICON; GM-CSF; HSV; IMMUNOTHERAPY; OVARIAN CANCER;

ANIMALS; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; FEMALE; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HERPESVIRUS 1, HUMAN; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; SURVIVAL; TUMOR NECROSIS FACTOR-ALPHA; VERO CELLS;

EID: 84897975482     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28631     Document Type: Article

References (48)

1. Torres MP, Ponnusamy MP, Lakshmanan I, et al. Immunopathogenesis of ovarian cancer. Minerva Medica 2009; 100: 385-400.
2. Cannistra SA,. Cancer of the ovary. New England J Med 2004; 351: 2519-29.
3. Chiocca EA,. Oncolytic viruses. Nat Rev 2002; 2: 938-50.
4. Esaki S, Goshima F, Kimura H, et al. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. Int J Cancer 2013; 132: 1592-601.
5. Kimata H, Takakuwa H, Goshima F, et al. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepato-Gastroenterol 2003; 50: 961-6.
6. Shimoyama S, Goshima F, Teshigahara O, et al. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Hepato-Gastroenterol 2007; 54: 1038-42.
7. Watanabe D, Goshima F, Mori I, et al. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatological Sci 2008; 50: 185-96.
8. Shah K, Breakefield XO,. HSV amplicon vectors for cancer therapy. Current Gene Therapy 2006; 6: 361-70.
9. Spaete RR, Frenkel N,. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 295-304.
10. Epstein AL,. HSV-1-based amplicon vectors: design and applications. Gene Ther 2005; 12: S154-8.
11. Jones T, Stern A, Lin R,. Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur J Clin Microbiol Infect Dis 1994; 13: S47-53.
12. Steinman RM,. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991; 9: 271-96.
13. Kohno SI, Luo C, Nawa A, et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Therapy 2007; 14: 918-26.
14. Hashimoto M, Niwa O, Nitta Y, et al. Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J Cancer Res 1989; 80: 459-63.
15. Nishiyama Y, Kimura H, Daikoku T,. Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2. J Virol 1991; 65: 4520-4.
16. Ushijima Y, Luo C, Goshima F, et al. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microbes Infection/Institut Pasteur 2007; 9: 142-9.
17. Nishiyama Y, Yoshida S, Maeno K,. Involvement of DNA polymerase alpha in host cell reactivation of UV-irradiated herpes simplex virus. J Virol 1984; 49: 598-600.
18. Fujiwara S, Nawa A, Luo C, et al. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Therapy 2011; 18: 77-86.
19. Esaki S, Goshima F, Katsumi S, et al. Apoptosis induction after herpes simplex virus infection differs according to cell type in vivo. Arch Virol 2010; 155: 1235-45.
20. Esaki S, Goshima F, Kimura H, et al. Auditory and vestibular defects induced by experimental labyrinthitis following herpes simplex virus in mice. Acta oto-laryngologica 2011; 131: 684-91.
21. Fujiwara H, Hamaoka T,. Coordination of chemokine and adhesion systems in intratumoral T cell migration responsible for the induction of tumor regression. Int Immunopharmacol 2001; 1: 613-23.
22. Roche MR, Rudd PJ, Krasner CN, et al. Phase II trial of GM-CSF in women with asymptomatic recurrent mullerian tumors. Gynecologic Oncol 2010; 116: 168-72.
23. Schmeler KM, Vadhan-Raj S, Ramirez PT, et al. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecologic Oncol 2009; 113: 210-5.
24. Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-47.
25. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27: 5763-71.
26. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Annals Surg Oncol 2010; 17: 718-30.
27. Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 2010; 16: 4005-15.
28. Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Annals Surg Oncol 2006; 13: 1078-84.
29. Nakao A, Takeda S, Shimoyama S, et al. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Current Cancer Drug Targets 2007; 7: 169-74.
30. Fujimoto Y, Mizuno T, Sugiura S, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta oto-laryngologica 2006; 126: 1115-7.
31. Cunningham C, Davison AJ,. A cosmid-based system for constructing mutants of herpes simplex virus type 1. Virology 1993; 197: 116-24.
32. Saeki Y, Fraefel C, Ichikawa T, et al. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001; 3: 591-601.
33. Boehmer PE, Lehman IR,. Herpes simplex virus DNA replication. Annual Rev Biochem 1997; 66: 347-84.
34. Zou JP, Yamamoto N, Fujii T, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 1995; 7: 1135-45.
35. Ogawa M, Umehara K, Yu WG, et al. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res 1999; 59: 1531-8.
36. Uekusa Y, Ogawa M, Gao P, et al. The development of peritumoral stroma required for IL-12 induced tumor regression depends on the T cell/IFN-gamma-involving host-tumor interaction. Int J Oncol 2000; 16: 805-14.
37. Nakajima C, Uekusa Y, Iwasaki M, et al. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer Res 2001; 61: 3399-405.
38. Roizman B, Knipe DM, Whitley RJ., Herpes simplex viruses. In:, Knipe DM, Howley PM, eds. Fields' virology, 5th edn., vol. 2. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2007. 2501-601.
39. Sica A, Porta C, Riboldi E, Locati M,. Convergent pathways of macrophage polarization: the role of B cells. Eur J Immunol 2010; 40: 2131-3.
40. Fernandez-Cruz E, Gilman SC, Feldman JD,. Altered levels of mononuclear leukocytes in tumor-bearing rats: decrease of helper T lymphocytes and increase of suppressor cells. J Immunol 1982; 129: 1324-8.
41. Gardner TE, Naama H, Daly JM,. Peritoneal and splenic macrophage functions in the tumor-bearing host. J Surg Res 1995; 59: 305-10.
42. Takahashi T, Ibata M, Yu Z, et al. Rejection of intradermally injected syngeneic tumor cells from mice by specific elimination of tumor-associated macrophages with liposome-encapsulated dichloromethylene diphosphonate, followed by induction of CD11b(+)/CCR3(-)/Gr-1(-) cells cytotoxic against the tumor cells. Cancer Immunol Immunother 2009; 58: 2011-23.
43. Pan PY, Li Y, Li Q, et al. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother 2004; 53: 17-25.
44. Huang AY, Bruce AT, Pardoll DM, et al. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter. Immunity 1996; 4: 349-55.
45. Mosmann TR, Sad S,. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-46.
46. Sad S, Marcotte R, Mosmann TR,. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity 1995; 2: 271-9.
47. Locksley RM, Killeen N, Lenardo MJ,. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
48. Yamamoto N, Zou JP, Li XF, et al. Regulatory mechanisms for production of IFN-gamma and TNF by antitumor T cells or macrophages in the tumor-bearing state. J Immunol 1995; 154: 2281-90.